Trial · NCT07421141
De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer
NCT07421141, Phase 2, Active not recruiting, National Medical Research Radiological Centre of the Ministry of Health of Russia
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer. Trials, record NCT07421141. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07421141
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer
- NCT number
- NCT07421141
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 186 participants, actual
- Lead sponsor
- National Medical Research Radiological Centre of the Ministry of Health of Russia
- Conditions
- Breast Cancer, HER2-positive Breast Cancer, Early Breast Cancer
- Interventions
- Paclitaxel, trastuzumab, Pertuzumab, Docetaxel, carboplatin, Radical Surgery, Adjuvant Systemic Therapy
- First posted
- 2026-02-19
- Last updated
- 2026-02-27
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pathological Complete Response (pCR) Rate | At the time of surgery (approximately 12-18 weeks after treatment initiation) | Defined as the absence of invasive cancer in the breast and axillary lymph nodes (ypT0/is ypN0) at the time of surgery |
| Secondary | Incidence of Grade 3-4 Adverse Events | From first dose until 30 days after last dose | Assessment of treatment-related toxicity (neutropenia, diarrhea, etc.) according to Common Terminology Criteria for Adverse Events (CTCAE) v5.0, where Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe, Grade 4 is life-threatening, and Grade 5 is death. |
| Secondary | Rate of Breast-Conserving Surgery | At the time of surgery | Proportion of patients eligible for and undergoing breast-conserving surgery |
| Secondary | 3-Year Event-Free Survival (EFS) | 3 years from enrollment | Time from enrollment to disease progression, local recurrence, distant metastasis, or death from any cause |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07421141
GET https://conductscience.org/api/trials/v1/NCT07421141/registered